28 May 2014

Pacific Edge sees lift in US earnings

1:00 pm on 28 May 2014

Cancer diagnostic company Pacific Edge says it has marked a significant commercial milestone with revenue starting to flow in its primary market - the United States.

The company's primary product is Cxbladder a non-invasive test that can detect bladder cancer in its early stages from a small volume of urine.

Pacific Edge chief executive David Darling said the company recorded a 187 percent lift in trading revenue to just over $0.5 million which is a strong lift given the brief time it has been selling in the American market.

Mr Darling said the company recorded a loss of just over $9 million but this was expected as part of setting up in the US.